EurekAlert! Cancer Research

News Releases

Updates every hour. Last Updated: 22-Jun-2026 03:16 ET (22-Jun-2026 07:16 GMT/UTC)

11-Mar-2026

IVF not linked to higher overall cancer rates, but study shows differences in some cancers

University of New South Wales
Peer-Reviewed Publication

A UNSW-led study found overall invasive cancer rates in Australian women were no higher after fertility treatments including IVF. Some specific cancers were slightly more common, while others were less common.

Journal: JAMA Network Open
Funder: National Health and Medical Research Council

10-Mar-2026

Diatom-based microrobots show promise for targeted photodynamic therapy of glioblastoma

Chinese Academy of Sciences Headquarters
Peer-Reviewed Publication

Researchers from the Shenyang Institute of Automation under the Chinese Academy of Sciences have developed magnetically controlled microrobots made from diatoms for the treatment of glioblastoma using photodynamic therapy. These microrobots exhibit excellent magnetic responsiveness and programmable motion capabilities, enabling them to precisely target and navigate to glioblastoma lesion areas.

Journal: Bio-Design and Manufacturing

10-Mar-2026

IU researchers identify clotting protein as potential target in pancreatic cancer

Indiana University
Peer-Reviewed Publication

Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center have found that depleting a clotting protein made by the liver could slow down pancreatic cancer.

Journal: Gastroenterology

10-Mar-2026

Scripps Research scientists awarded nearly $5 million by NIH to investigate cancer growth

Scripps Research Institute
Grant and Award Announcement

Researchers will investigate how a common dietary nutrient may control a hidden layer of gene regulation in cancer cells.

10-Mar-2026

Wistar scientists develop two-vaccine strategy to fight t cell lymphoma

The Wistar Institute
Peer-Reviewed Publication

Wistar Institute scientists have designed a two-vaccine approach that not only targets the tumors’ unique molecular identity but counters the evasion strategy the cancer employs in response.

Journal: Cancer Immunology Immunotherapy
Funder: Cancer Center Support Grant, WW Smith Charitable Trust Distinguished Professorship in Cancer Research, Geneos Therapeutics-sponsored research agreement, The Jill and Mark Fishman Foundation, Inovio Pharmaceuticals-sponsored research agreement

10-Mar-2026

Ochsner MD Anderson to be first in the southern U.S. to offer precision cancer radiation treatment

Ochsner Health System
Business Announcement

The new treatment uses the unique biology of the cancer itself to guide radiotherapy delivery, even in tumors that are in motion.

10-Mar-2026

Low testosterone levels may be associated with increased risk of prostate cancer progression during surveillance

University of Texas M. D. Anderson Cancer Center
Peer-Reviewed Publication

A new study led by researchers at The University of Texas MD Anderson Cancer Center found that prostate cancer patients with low testosterone levels may have a higher risk of cancer progressing to a more aggressive form while under active surveillance.

Journal: The Journal of Urology

10-Mar-2026

Female reproductive cancers and the sex gap in survival

JAMA Network
Peer-Reviewed Publication

About The Study: In this population-level cohort study of 20 low-mortality countries, females ages 35 to 60 experienced disadvantage in cancer mortality compared with males—a consistent pattern observed across birth cohorts and over time. These findings underscore the ongoing need for action on the prevention, early detection, and treatment of early-onset female reproductive cancers.

Journal: JAMA Network Open

10-Mar-2026

Study identifies gene linked to chemotherapy resistance in prostate cancer

Weill Cornell Medicine
Peer-Reviewed Publication

A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel Deaconess Medical Center. The findings provide important new insights into why patients with metastatic disease often stop responding to a key class of life-prolonging chemotherapy drugs after initially benefiting. Given that taxanes remain the only chemotherapy agents with demonstrated survival benefit in advanced prostate cancer, understanding how and why resistance develops is an urgent need for patients.

Journal: Nature Communications

10-Mar-2026

Targeted treatments plus engineered immune cells may slow early spread of triple‑negative breast cancer, study reveals

Houston Methodist
Peer-Reviewed Publication

A new study has revealed a promising new approach to curb the spread of triple‑negative breast cancer, one of the most aggressive and difficult‑to‑treat forms of the disease.

Published recently in Cancer Letters, Gabriel Duda, Ph.D., scientific director of transplant oncology and therapeutics at Houston Methodist Research Institute, and his research team discovered pairing targeted treatments with CAR T‑cell therapy may help control cancer recurrence when intervention options are otherwise limited.

Journal: Cancer Letters